Physician profile
Lacy M Windham
NPI 1750542494
$2,331.88
in general payments reported to CMS, 2019-2025
22 companies · $452 in 2025
The $452 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $135 · 2021: $57.19 · 2022: $284 · 2023: $565 · 2024: $674 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,691.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $427.47 | 2023-2025 | Myfembree, Gemtesa |
| Sage Therapeutics, LLC | $287.06 | 2023-2025 | Zurzuvae |
| Exeltis, USA INC. | $285.79 | 2020-2025 | Slynd, Twirla |
| Abbvie INC. | $276.02 | 2019-2023 | Ubrelvy, Qulipta, Orilissa |
| Astellas Pharma US INC | $249.26 | 2024 | Veozah |
| Mayne Pharma Commercial LLC | $127.86 | 2022-2025 | |
| Pfizer INC. | $115.00 | 2020-2025 | |
| Ethicon US, LLC | $67.61 | 2022-2023 | Dermabond, Ethicon, Stratafix |
| Boston Scientific Corporation | $58.93 | 2022-2025 | General - Erectile Dysfunction |
| Daiichi Sankyo INC. | $55.31 | 2023-2024 | Injectafer |
| Organon LLC | $47.64 | 2024-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $45.27 | 2019-2022 | |
| Allergan, INC. | $42.17 | 2019-2021 | |
| Myovant Sciences INC. | $39.86 | 2022 | |
| Avion Pharmaceuticals | $38.67 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $37.67 | 2025 | Qelbree |
| Therapeuticsmd, INC. | $36.27 | 2019 | |
| Hologic Sales and Service, LLC | $27.98 | 2022-2024 | Myosure Tissue Removal Device |
| Medtronic, INC. | $18.44 | 2024 | Venaseal |
| Urovant Sciences INC | $18.26 | 2022 | |
| Shield Therapeutics INC | $17.71 | 2023 | Accrufer |
| Minerva Surgical, INC | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacy Windham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.